Qiming Venture Partners

🔊 Looking back, what Qiming Venture Partners has achieved? Find out more in 60 seconds.

Zencore Biologics, a portfolio company of Qiming Venture Partners, has entered into a strategic commercialization production agreement with DualityBio, marking a significant milestone in their collaboration. This agreement strengthens their long-term partnership in large-scale production and supply, while also paving the way for future innovations and global market expansion. Jianxin Chen, Chairman and CEO of Zencore Biologics, said, "Zencore Biologics is committed to advancing the scaling and internationalization of biopharmaceutical production. DualityBio, a leader in ADC innovation, will continue to develop next-generation ADCs, including bispecific ADCs, novel payload mechanism ADCs, and auto-immune ADCs, on its path to becoming a global leader in ADC biopharmaceuticals. We are honored to collaborate with DualityBio and support them in delivering high-quality, cost-effective commercial production." #Biotechnology #ADCInnovation #Commercialization #GlobalExpansion #Biopharmaceuticals #StrategicPartnership #QimingPortfolio #QimingHealthcare

Aohua Endoscopy Co., Ltd. (SHSE:688212), a portfolio company of Qiming Venture Partners, has introduced its innovative dual-channel endoscope. This advanced endoscope is designed for therapeutic procedures, enabling the simultaneous use of multiple medical devices. By mimicking a "two-handed" approach, it allows for faster and more efficient actions like biopsy, hemostasis, and excision. The dual-channel design reduces the need for frequent accessory changes and addresses the limitations of single-channel models, offering greater flexibility to navigate complex diagnostic and treatment scenarios. #MedicalInnovation #Endoscopy #TherapeuticSolutions #HealthcareTechnology #SurgicalInnovation #PatientCare #HealthcareExcellence #QimingPortfolio #QimingHealthcare

Dr. Alan J. Korman, a globally recognized leader in tumor immunology and a key pioneer in immune checkpoint blockade (ICB) therapies, has joined the Scientific Advisory Board (SAB) of LTZ Therapeutics, a Qiming Venture Partners' portfolio company. Dr. Alan J. Korman's appointment further strengthens LTZ Therapeutics' innovative capabilities. He joins an esteemed group of experts, including Dr. Sarah Hymowitz, Dr. Greg Cosma, Dr. Lukas Amler, Dr. Lillian L. Siu, Dr. Stephen Beers, and Professor Hiroyoshi Nishikawa. With over 40 years of experience in both academia and industry, Dr. Korman played a critical role in the development of ICB therapies, including treatments such as Yervoy® (Ipilimumab), Opdivo® (Nivolumab), and Opdualag® (Relatlimab + Nivolumab). These therapies have become first-line treatments for various cancers, transforming patient outcomes and significantly advancing the field of immuno-oncology. #ImmunoOncology #CancerTherapy #InnovativeMedicine #ICB #ScientificAdvisoryBoard #AlanJKorman #HealthcareInnovation #OncologyLeadership #QimingPortfolio #QimingHealthcare

Qiming Venture Partners' portfolio company, ROX Motor, has announced the launch of ROX LIFE, a new brand focused on enhancing the refined outdoor lifestyle. ROX LIFE offers a curated collection of high-quality outdoor gear for activities such as fishing, camping, and hiking, designed to elevate the outdoor experience. With a focus on stylish and thoughtful products, ROX LIFE aims to provide outdoor enthusiasts with things they need to create their perfect adventure, blending design, comfort, and joy. #OutdoorLifestyle #ROXLIFE #OutdoorAdventure #Fishing #Camping #Hiking #OutdoorGear #Sustainability #InnovativeDesign #QimingPortfolio #QimingTechnologyandConsumer

M20 Genomics, a Qiming Venture Partners' portfolio company, supported cutting-edge research recently published in Scientific Data, with an impact factor of 5.8. The collaborative effort by Hangzhou City University, Zhejiang University, and Liangzhu Laboratory resulted in the paper titled "snRNA-seq of long-preserved FFPE samples from colorectal liver metastasis lesions with diverse prognoses." The study utilized M20 Genomics' VITA platform to perform single-cell transcriptome analysis on 18 FFPE samples of metastatic colorectal cancer lesions with varying prognoses. This research offers valuable insights into the heterogeneity of colorectal cancer liver metastases, exploring differences between lesions with distinct prognoses and the relationship between intra-lesion heterogeneity and patient outcomes. #ScientificData #CancerResearch #SingleCellAnalysis #Biotechnology #FFPE #PrecisionMedicine #OncologyInnovation #QimingPortfolio #QimingHealthcare

We are pleased to announce that Qiming Venture Partners' portfolio company HyperStrong, a leading provider of battery energy storage systems (BESS) in China, successfully debuted on the Shanghai Stock Exchange's Science and Technology Innovation Board (the "STAR Market"). Qiming Venture Partners has been an early investor in HyperStrong since 2015 and has continued to support the company's growth through subsequent funding rounds. HyperStrong's successful IPO marks Qiming's first IPO milestone of 2025. Founded in 2011, HyperStrong has established itself as a trusted partner in the global transition to renewable energy. The company provides a wide range of energy storage solutions including liquid-cooling energy storage systems, outdoor cabinets, all-in-one charging and storage systems for utility-scale, commercial and industrial uses. Alex Zhou, Managing Partner of Qiming Venture Partners, said, "Over the past decade, we have supported HyperStrong as an investor, shareholder, and board member, steadfastly accompanying the company throughout its remarkable growth. We have witnessed HyperStrong leverage its cutting-edge R&D, strategic market insights, and relentless spirit of innovation to become a leader in the competitive energy storage industry. Today's successful IPO is not only a major milestone in its journey but also the start of an exciting new chapter full of potential. As the global energy sector undergoes a transformative shift, energy storage has become a critical pillar of this change. We expect HyperStrong to continue leading the way in technological innovation, solidifying its position as a key player in the global energy storage market." #EnergyStorage #BatteryStorage #BESS #RenewableEnergy #SustainableEnergy #EnergyTransition #IPO #Innovation #TechMilestone #EnergySolutions #CleanEnergy #GlobalEnergy #CleanTech #Sustainability #EnergyFuture #QimingPortfolio #QimingTechnologyandConsumer Read More: https://lnkd.in/gVmHsy4n

MEDx, a portfolio company of Qiming Venture Partners, played a key role in a recent clinical study published in The Lancet Oncology. The study focuses on CMG901, a novel targeted Claudin 18.2 (CLDN18.2) antibody-drug conjugate. MEDx provided critical CLDN18.2 antibody reagents and biomarker testing services, supporting the trial's success and advancing precision treatments for gastric cancer. This study is a multi-center, open-label, single-arm Phase 1 trial (KYM901) that assessed the antitumor activity and safety of CMG901 in patients with advanced gastric cancer or gastroesophageal junction cancer. MEDx's central laboratory played a pivotal role in testing CLDN18.2 expression levels during the trial. In the dose escalation phase, tumor samples were retrospectively analyzed for CLDN18.2 expression. Patients whose tumors showed a membrane staining intensity of at least 2+ and expression in at least 5% of tumor cells were included in the dose expansion phase. This approach lays a solid foundation for precision screening and future treatment optimization. #PrecisionOncology #ClinicalResearch #GastricCancer #Biomarkers #HealthcareInnovation #TargetedTherapy #Claudin18.2 #QimingPortfolio #QimingHealthcare

Fortune Care, a portfolio company of Qiming Venture Partners, was officially inducted as a member of the Wanaixi Aging Care Alliance, recognized by the Shanghai Mental Health Center, Shanghai Jiao Tong University AD Diagnosis and Treatment Center, and the Core Advanced Cognitive Disorder Diagnosis and Treatment Center. This recognition underscores Fortune Care's leadership and commitment to advancing care for individuals with cognitive disorders. With a strong focus on dementia care, Fortune Care has developed an integrated professional care model to deliver specialized services for elderly patients with cognitive impairments. Currently, the company's services extend across more than 20 cities in China, with over 270 care centers nationwide, providing support to more than 100,000 patients annually. Fortune Care's multidisciplinary team includes cognitive disorder experts, doctors, nurses, rehabilitation therapists, cognitive intervention specialists, and over 1,000 professional dementia care workers. #ElderlyCare #CognitiveDisorders #DementiaCare #HealthcareInnovation #SeniorCare #AgingPopulation #HealthTech #QimingPortfolio #QimingHealthcare

Insight Lifetech Co., Ltd. , a portfolio company of Qiming Venture Partners, has secured the Class III Medical Device Registration Certificate from the China National Medical Products Administration (NMPA) for the latest model in the TrueExtensio® Extension Catheter Series. The TrueExtensio® series incorporates Insight Lifetech's advanced vascular intervention technology, featuring an innovative "self-coaxial" function that enables the catheter to automatically adjust its path in tortuous vessels. This design ensures superior trackability, efficient delivery, and enhanced safety, addressing the clinical challenges of navigating complex lesions without the need for auxiliary devices. #MedTechInnovation #VascularIntervention #TrueExtensio #NMPAApproval #MedicalTechnology #HealthcareInnovation #LifeSciences #CatheterTechnology #QimingPortfolio #QimingHealthcare